Khalifa Kush enters Australia medical cannabis market through a national distribution agreement with Endoca, the companies announced in a June 16, 2026 press release. The Los Angeles–based brand, founded by recording artist Wiz Khalifa, will roll out an initial lineup of premium flower and edible products to patients and clinics across Australia.
Khalifa Kush identified Australia as its sixth global market. The partnership with Endoca covers distribution to pharmacies and clinics in all six states and two territories, enabling supply across mainland Australia and major population centers. The companies said the initial product set will include high-quality flower and packaged edible formulations built on Khalifa Kush proprietary genetics.
Khalifa Kush CEO DJ Saul said the brand is selective about market entries and will focus on markets with established regulation and patient access. “We’re not entering every market; we’re entering the right markets,” Saul said in the release, adding that the Endoca agreement will help “maintain brand integrity and deliver the quality that patients and consumers expect from KK.”
Endoca Managing Director Johnny Jusic described the deal as a way to introduce Khalifa Kush genetics into Australia’s regulated medical framework. Jusic said Endoca will manage local regulatory compliance and manufacturing standards to deliver products through health-care channels.
Key facts: – Launch date announced: June 16, 2026 (press release date). – Market count: Australia is Khalifa Kush’s sixth international market. – Distribution: Pharmacies and clinics across all six Australian states (New South Wales, Victoria, Queensland, Western Australia, South Australia, Tasmania) and two territories (Australian Capital Territory and Northern Territory). – Initial product types: Premium flower and edibles, formulated from Khalifa Kush genetics.
Khalifa Kush positions the move as part of a measured global expansion. The brand has previously launched products in North America and Europe; this agreement establishes a presence in the Asia-Pacific region with a regulated, patient-focused channel. The companies highlighted patient access as a priority, noting Australia’s established medical cannabis pathways for prescribing and dispensing.
From a regulatory perspective, Australia requires medical cannabis products to meet local manufacturing and quality standards when they are supplied through pharmacies and clinics. Endoca will oversee local compliance and health-care-led distribution, according to the announcement. That includes meeting relevant Good Manufacturing Practice (GMP) or equivalent standards used in Australia’s regulated supply chains.
Business impact and market context: Australia’s medical cannabis market has shown year-over-year growth in patient numbers and prescriptions since the country expanded access pathways. Exact market-size figures vary by source, but industry analysts rank Australia among the faster-growing medical cannabis markets globally due to increasing patient uptake and prescriber familiarity.
Khalifa Kush aims to leverage its cultivar lineage and brand recognition to capture a share of patient demand for consistent flower genetics and branded edible options. The company emphasized product consistency and traceability as central selling points for medical dispensaries and clinicians that require repeatable dosing and predictable chemotype profiles.
Operational notes: Endoca will handle regulatory filing, local manufacturing or contract manufacturing oversight, and distribution logistics to ensure product availability in clinics and pharmacies. The announcement did not disclose pricing, launch timeline for specific SKUs, or manufacturing locations. The companies said more product and availability details will follow as regulatory approvals and supply chain steps are completed.
Brand and founder background: Khalifa Kush was created by musician Wiz Khalifa and markets itself on proprietary genetics and consumer-facing product design. The brand described its offering as “premium” and emphasized consistency across batches. The press release noted prior launches in North America and Europe but did not provide sales figures or market share data.
What to watch next: – Regulatory approvals: Local scheduling, product registration, and any required import or domestic manufacturing approvals. – Product rollouts: Exact SKUs, THC/CBD concentrations, dosing information for edibles, and lab-test results. – Distribution timing: When products will first appear in pharmacies and clinics in major metropolitan areas such as Sydney, Melbourne, and Brisbane.
For more information, the companies pointed readers to khalifakush.com and the brand’s Instagram channel @khalifakush. The announcement frames this agreement as a commercial launch aimed at supplying regulated health-care channels with branded flower and edible options built on Khalifa Kush genetics.
